GlassScriptPhysician profile
Samuel H Favela
NPI 1245391754
$3,026.99
in general payments reported to CMS, 2019-2025
26 companies · $801 in 2025
The $801 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $147 · 2021: $160 · 2022: $719 · 2023: $634 · 2024: $379 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,064.87 | 2020-2025 | |
| Biotissue Holdings INC. | $396.17 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $260.50 | 2024-2025 | Xdemvy |
| Abbott Laboratories | $223.40 | 2023 | Freestyle Libre 3 |
| Abbvie INC. | $167.60 | 2022-2025 | |
| Insulet Corporation | $142.61 | 2023 | Omnipod |
| Alcon Vision LLC | $127.92 | 2021-2025 | Eysuvis, Clareon |
| Astellas Pharma US INC | $84.18 | 2019-2025 | Izervay |
| Lilly USA, LLC | $82.84 | 2023 | Mounjaro |
| Allergan, INC. | $81.15 | 2020-2021 | |
| Amgen INC. | $59.25 | 2023-2025 | Tepezza, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $47.52 | 2023 | |
| Janssen Pharmaceuticals, INC | $34.92 | 2020 | |
| Harrow Eye, LLC | $30.80 | 2024 | Vevye |
| Mallinckrodt Hospital Products INC. | $30.49 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $27.91 | 2025 | Tyrvaya |
| Takeda Pharmaceuticals U.S.A., INC. | $27.45 | 2021 | |
| Aurinia Pharma U.S., INC. | $22.97 | 2023 | Lupkynis |
| Shire North American Group INC | $20.13 | 2019 | |
| Radius Health, INC. | $14.46 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.98 | 2022 | |
| Bausch & Lomb Americas INC. | $13.80 | 2025 | Miebo |
| Novartis Pharmaceuticals Corporation | $13.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.13 | 2023 | Cyltezo |
| Kowa Pharmaceuticals America, INC. | $12.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Favela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.